A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors

Digestive Diseases and Sciences

Volumn 51, Issue 6, 2006, Pages 1033-1038

  Kulke, Matthew H ^a   Wu, Bingyan ^a   Ryan, David P ^b   Enzinger, Peter C ^a   Zhu, Andrew X ^b   Clark, Jeffrey W ^b   Earle, Craig C ^a   Michelini, Ann ^a   Fuchs, Charles S ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Carcinoid tumors; Cisplatin; Irinotecan; Neuroendocrine tumors; Pancreatic islet cell tumors

Indexed keywords

CISPLATIN; IRINOTECAN;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LEUKOCYTE COUNT; MALE; MUSCLE CRAMP; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TUMOR DIFFERENTIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DIGESTIVE SYSTEM NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33746449124     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-8001-3     Document Type: Article

References (22)

1. DiBartolomeo M, Bajetta E, Buzzoni R, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 77:402-408, 1996
2. Capella C, Heitz P, Hofler H, Solcia E, Kloppel G: Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch 425:547-560, 1995
3. Moertel C, Kvols L, O'Connell M, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227-232, 1991
4. Fjallskog M, Granberg D, Welin S, et al.: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101-1107, 2001
5. Cunningham D, Pyrhonen S, James RD, et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138):1413-1418, 1998
6. Saltz L, Cox J, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
7. Saltz L, Spriggs D, Schaaf L, et al.: Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 16:3858-3865, 1998
8. Ilson DH, Saltz L, Enzinger P, et al.: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17(10):3270-3275, 1999
9. Kudoh S, Fujiwara Y, Takada Y, et al.: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16:1068-1074, 1998
10. Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
11. Hou Z, Elasmar A, Lozano R, et al.: A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proc Am Soc Clin Oncol 22:A1508, 2003
12. Moertel C, Hanley J: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2:327-334, 1979
13. Engstrom P, Lavin P, Moertel C, Folsch E, Douglass H: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2:1255-1259, 1984
14. Moertel C, Lefkopoulo M, Lipsitz S, Hahn R, Klaassen D: Streptozocin-doxorubicin, stretpozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523, 1992
15. Cheng P, Saltz L: Failure to confirm major objective antitumor activity ofr streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86:944-948, 1999
16. McCollum A, Kulke M, Ryan D, et al.: Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 27:485-488, 2004
17. Kouvaraki M, Ajani J, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762-4771, 2004
18. Bukowski R, Tangen C, Peterson R, et al.: Phase II trial of dimethyl-triazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 73:1505-1508, 1994
19. Ramanathan R, Cnaan A, Hahn R, Carbone P, Haller D: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group. Ann Oncol 112:1139-1143, 200
20. Ansell S, Pitot H, Burch P, Kvols L, Mahoney M, Rubin J: A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91:1543-1548, 2001
21. Kulke M, Kim H, Stuart K, et al.: A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest22:353-359, 2004
22. Kulke M, Kim H, Clark J, et al.: A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101:934-939, 2004